All In Biotech

Drug Trial Radar · NCT00286273

Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration

Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin

Last checked: Nov 20, 2026Latest source record: Aug 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 215 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

215

Actual

Start

Mar 2003

Primary completion

Jan 2008

Study completion Mar 2008

Sponsor

Lead sponsor
Onze Lieve Vrouwe GasthuisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications. Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.

Conditions

  • Kidney Failure, Acute

Interventions

  • trisodium citrateDrug

    for regional anticoagulation of the extracorporeal CVVH circuit

  • nadroparinDrug

    for anticoagulation of the extracorporeal CVVH circuit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. bleeding complicationsTime frame: during administration of study anticoagulant
  2. transfusion requirementTime frame: during administration of study anticoagulant
  3. filter survivalTime frame: during hemofiltration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Onze Lieve Vrouwe Gasthuis

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.